EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against American Renal Associates Holdings, Inc. - ARA

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of American Renal Associates Holdings, Inc. (NYSE:ARA) resulting from allegations that American Renal Associates may have issued materially misleading business information to the investing public.

According to recent news reports, and a complaint filed by UnitedHealth Group, Inc., American Renal Associates has allegedly steered patients away from Medicare and Medicaid programs into higher paying Affordable Care Act programs. On August 18, 2016, the Centers for Medicare and Medicaid Services said it sent warning letters to all dialysis centers that participate in the Medicare program and is weighing financial penalties on providers who are found to have directed people eligible for Medicare into Affordable Care Act plans instead. On this news, shares of American Renal Associates fell $2.31 per share or over 10% to close at $19.81 per share on August 19, 2016.

Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by American Renal Associates investors. If you purchased shares of American Renal Associates on or before August 18, 2016, please visit the firm’s website at http://www.rosenlegal.com/cases-946.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or kchan@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160826005783/en/